AKT1 and ovarian carcinoma: Previous research has demonstrated that the constitutive activation of AKT in various ovarian cancer cell lines (e.g., SK-OV-3, OVCAR-4, and OVCAR-5) promotes cell survival and resistance to cisplatin.